3 April 2024 - AB Science today announced that Health Canada has granted eligibility for reconsideration request for masitinib in amyotrophic lateral sclerosis (ALS). The reconsideration process will re-examine, with new assessors, the decision based on information that was included in the original submission.

A notice of deficiency-withdrawal was issued on 19 February 2024 by Health Canada regarding the new drug submission for masitinib in the treatment of ALS. The intention to submit a reconsideration request was based on the arguments summarised in the press release dated 26 February 2024.

Read AB Science press release